Treatment of advanced renal cell carcinoma with IFN-α, VLB and UFT

T. Saika, K. Kobashi, T. Tsushima, Y. Nasu, M. Noda, H. Ohmori, Y. Matsumura, T. Akaeda, M. Hara, N. Ike, K. Kondo, T. Asahi, M. Saegusa, T. Johsen



The therapeutic efficacy of immuno-chemotherapy was evaluated in patients with advanced renal cell carcinoma. Fifteen patients received induction therapy, a combination of human lymphoblastoid interferon (HLBI) (3 x 106 IU, i.m. every day) plus vinblastine (VLB) (3mg/m2, i.v. once a week) with (Group A) or without (Group B) UFT (a compound of Tegafur and uracil) (300mg/body, p.o. every day), and maintenance therapy, a combination of HLBI (3 x 106 IU, i.m. 3 days a week) plus VLB (3mg/m2, i.v. once a month) with (Group A) or without (Group B) UFT (300mg/body, p.o. every day). Twelve patients (6 of Group A and 6 of Group B) were evaluable for their response to the treatment. There were no patients who showed a complete response (CR). One patient of Group A (8% of overall) experienced a partial response (PR), while 2 of Group A, and 1 of Group B showed a minor response (MR). The response duration of PR patients was 8 months. Toxicity was evaluable in 13 patients. Anorexia, general fatigue and leukopenia were most common, and these were observed in about 70% of patients. In addition, one patient withdrew from the trial because of anal bleeding. The average duration of survival was 10.0 months. Our results suggest that combination immunochemotherapy with HLBI, VLB and UFT for advanced renal cell carcinoma is not excellent when compared with HLBI alone.

ジャーナルNishinihon Journal of Urology
出版ステータスPublished - 1994

ASJC Scopus subject areas

  • 泌尿器学


「Treatment of advanced renal cell carcinoma with IFN-α, VLB and UFT」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。